KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Operating Margin (2016 - 2025)

Historic Operating Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 14.38%.

  • Neogenomics' Operating Margin fell 17500.0% to 14.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.04%, marking a year-over-year decrease of 27200.0%. This contributed to the annual value of 13.94% for FY2024, which is 42700.0% up from last year.
  • As of Q3 2025, Neogenomics' Operating Margin stood at 14.38%, which was down 17500.0% from 26.27% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Operating Margin registered a high of 10.7% during Q4 2024, and its lowest value of 44.4% during Q1 2022.
  • Its 5-year average for Operating Margin is 21.59%, with a median of 19.02% in 2022.
  • As far as peak fluctuations go, Neogenomics' Operating Margin plummeted by -374600bps in 2021, and later skyrocketed by 188400bps in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Operating Margin stood at 33.06% in 2021, then skyrocketed by 42bps to 19.02% in 2022, then surged by 37bps to 11.94% in 2023, then increased by 10bps to 10.7% in 2024, then tumbled by -34bps to 14.38% in 2025.
  • Its last three reported values are 14.38% in Q3 2025, 26.27% for Q2 2025, and 16.56% during Q1 2025.